Taylor Colman, Wonder Michael
The George Institute for Global Health, PO Box M201 Missenden Road, Camperdown, NSW 2050, Australia.
Wonder Drug Consulting Pty Ltd, PO Box 470, Cronulla, NSW 2230, Australia. Email.
Aust Health Rev. 2015 Sep;39(4):455-461. doi: 10.1071/AH14122.
Spending on medicines under the Pharmaceutical Benefits Scheme (PBS) represents the ninth largest expense to the Federal Government. A recent report by the Commission of Audit to the Federal Government suggested spending on the PBS is unsustainable and a capped budget, similar to New Zealand's PHARMAC model, may be required to contain costs. The objective of the present study was to compare listing outcomes between Australia and New Zealand, thereby exploring the opportunity cost of a capped budget for new medicines.
Listing outcomes in Australia and New Zealand were compared through published research and an updated search of listing outcomes from publicly available information.
Previous research has demonstrated that New Zealand listed less than half of the new medicines listed in Australia over a 10-year period (2000-09). Our research shows that most of the new medicines not listed in New Zealand during this period remain unlisted today. In the previous 12 months, Australia listed 17 new medicines on the PBS, whereas New Zealand listed only one new medicine that was not already listed in Australia.
The discrepancy in the number of new medicines listed in New Zealand compared with Australia raises questions regarding the consequences of implementing a capped budget for new medicines. However, further research is needed to understand the relationship between listing outcomes, access to medicines and health benefits for the community.
药品福利计划（PBS）下的药品支出是联邦政府的第九大支出项目。审计委员会最近向联邦政府提交的一份报告表明，PBS的支出是不可持续的，可能需要采用类似于新西兰药品管理局（PHARMAC）模式的预算上限来控制成本。本研究的目的是比较澳大利亚和新西兰的药品上市结果，从而探讨新药预算上限的机会成本。
通过已发表的研究以及对公开信息中上市结果的更新搜索，比较澳大利亚和新西兰的上市结果。
先前的研究表明，在2000年至2009年的10年期间，新西兰上市的新药不到澳大利亚的一半。我们的研究表明，在此期间未在新西兰上市的大多数新药如今仍未上市。在过去12个月中，澳大利亚在PBS上列出了17种新药，而新西兰仅列出了一种未在澳大利亚上市的新药。
与澳大利亚相比，新西兰新药上市数量的差异引发了有关对新药实施预算上限后果的疑问。然而，需要进一步研究以了解上市结果、药品可及性和社区健康效益之间的关系。
